Literature DB >> 947576

Nitroprusside after open-heart surgery.

G Benzing, J A Helmsworth, J T Schrieber, J Loggie, S Kaplan.   

Abstract

The effects of intravenous infusion of sodium nitroprusside were studied in 11 children immediately after open-heart surgery for congenital heart disease. The patients were selected because, following bypass, their cardiac index was below 2,0 L/min/m2 and their systemic vascular resistance exceeded 30 units. In order to eliminate the effects of preload, mean left atrial pressure was maintained at a constant level by blood transfusion. During infusion of nitroprusside the mean decrease of mean arterial pressure was 18.6%, of systemic vascular resistance was 53.7%, and the increase in cardiac index was 76.9%. All children recovered.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947576     DOI: 10.1161/01.cir.54.3.467

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Nitroprusside-epinephrine administration in acute myocardial ischemia.

Authors:  H I Pass; M D Turner; W A Neely; F A Crawford
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

2.  Vasodilator therapy for cardiac failure in pediatric practice.

Authors:  P S Rao
Journal:  Indian J Pediatr       Date:  1982 Nov-Dec       Impact factor: 1.967

Review 3.  New drug approaches to the treatment of heart failure in infants and children.

Authors:  S Kaplan
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  Nitroprusside in children after cardiopulmonary bypass: a study of thiocyanate toxicity.

Authors:  S Kunathai; G F Sholler; J M Celermajer; M O'Halloran; T B Cartmill; G R Nunn
Journal:  Pediatr Cardiol       Date:  1989       Impact factor: 1.655

5.  Experts' recommendations for the management of cardiogenic shock in children.

Authors:  Olivier Brissaud; Astrid Botte; Gilles Cambonie; Stéphane Dauger; Laure de Saint Blanquat; Philippe Durand; Véronique Gournay; Elodie Guillet; Daniela Laux; Francis Leclerc; Philippe Mauriat; Thierry Boulain; Khaldoun Kuteifan
Journal:  Ann Intensive Care       Date:  2016-02-16       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.